The CAPItello-291, monarchE, RIGHT Choice, and EMERALD trials have shown favorable outcomes for patients with HR+, HER2- breast cancer.
Adding carboplatin to standard neoadjuvant chemotherapy improved outcomes in younger patients with triple-negative breast cancer.
Combination cemiplimab, REGN3767, and chemotherapy appears effective in triple-negative breast cancer and HR+, HER2- breast cancer.
Patients with germline pathogenic variants in BRCA1, BRCA2, and CHEK2 have an increased risk of contralateral breast cancer.
Interrupting endocrine therapy so patients with breast cancer can attempt pregnancy does not appear to impact short-term disease outcomes.
Continuing CDK4/6 inhibitor therapy and switching ET after disease progression does not improve progression-free survival vs switching ET alone in HR+, HER2- metastatic breast cancer.
Camizestrant improved progression-free survival vs fulvestrant in postmenopausal patients with ER+, HER2- advanced breast cancer.
Neoadjuvant trastuzumab deruxtecan appears active in patients with HER2-low, hormone receptor-positive, early breast cancer.
Adding capivasertib to treatment with fulvestrant improved progression-free survival in aromatase inhibitor-resistant, HR+, HER2- advanced breast cancer.
The duration of prior treatment with a CDK4/6 inhibitor appears to impact progression-free survival with elacestrant in ER+/HER2- metastatic breast cancer.
Ribociclib plus endocrine therapy prolongs progression-free survival when compared with chemotherapy in HR+/ HER2− advanced breast cancer.
A retrospective study revealed characteristics of patients with metastatic breast cancer who are not likely to receive first-line systemic therapy.
The Breast Cancer Index can predict benefit from ovarian function suppression in premenopausal patients with HR+, early-stage breast cancer.
Trastuzumab deruxtecan improves overall survival vs trastuzumab emtansine in previously treated, HER2-positive, advanced breast cancer, a phase 3 trial suggests.
Patients with HR+/HER2-, intermediate-risk, early breast cancer can forgo chemotherapy without increasing their risk of late recurrence, updated data suggest.
Adding abemaciclib to adjuvant endocrine therapy can provide long-term benefits for patients with high-risk, HR+, HER2- early breast cancer, updated data suggest.
Trastuzumab deruxtecan improves outcomes vs physician’s choice of treatment in patients with previously treated, HER2+, advanced breast cancer.
Adding everolimus to adjuvant endocrine therapy does not improve survival for patients with HR+, HER2- breast cancer.
Adding chemotherapy to endocrine therapy leads to greater cognitive impairment in postmenopausal patients with breast cancer, a study suggests.
Aromatase inhibitors improved disease-free survival when compared with tamoxifen in HR+, HER2- early breast cancer, regardless of menopausal status.